Safe Use of Biologics and Monoclonal Antibodies

This Continuing Education (CE) course is designed for Registered Nurses (RNs) and Nurse Practitioners seeking a comprehensive understanding of biologics and monoclonal antibodies, with a focus on their safe and effective integration into nursing practice. As the use of biologics continues to expand across a wide range of therapeutic areas—including oncology, rheumatology, dermatology, gastroenterology, infectious disease, and immunology—nurses must stay informed about the pharmacological principles, regulatory guidelines, and patient safety considerations associated with these advanced therapies.

Biologics are large, complex molecules produced from living organisms through highly controlled biotechnological processes. Unlike traditional small-molecule drugs, biologics have unique pharmacodynamics, manufacturing standards, and mechanisms of action, requiring specialized knowledge to manage their administration and potential side effects. This course will help nurses distinguish biologics from small-molecule medications, understand biosimilars, and appreciate the nuances of therapeutic equivalence and interchangeability. Key pharmacological and clinical implications will be explored, including the impact of immunogenicity on drug efficacy and safety.

Participants will examine the regulatory processes involved in the development, approval, and classification of biologics, including the role of the U.S. Food and Drug Administration (FDA) and the Biologics Control Act. Nurses will also learn how to evaluate adverse drug reactions using frameworks like the Gell and Coombs classification of hypersensitivity reactions (Types I–IV), enabling better identification and management of patient responses to therapy.

One of the critical aspects of biologic use in clinical settings is managing immune-related complications such as cytokine release syndrome, serum sickness, and infusion-related reactions. This course provides practical guidance on recognizing systemic syndromes associated with biologic therapies, addressing their underlying pathophysiology, and implementing appropriate interventions.

Evidence-based strategies to monitor for hypersensitivity reactions and improve patient outcomes are emphasized. Nurses will learn pre-medication protocols, risk factors, and desensitization techniques for patients who have previously experienced adverse reactions. Case-based scenarios and real-world clinical considerations will help solidify understanding and improve clinical decision-making.

Through this course, participants will also strengthen their patient education and communication skills, equipping them to effectively explain biologic therapies, their benefits, potential side effects, and self-monitoring techniques to patients and caregivers.

By the end of this course, nurses will have the expertise needed to promote the safe and evidence-based use of biologics in a variety of healthcare settings, contributing to improved therapeutic outcomes and patient-centered care.

Educational Objectives

After completing this activity, learners will be able to:

• Examine the regulatory processes involved in approving and classifying biologics.
• Differentiate between types of adverse drug reactions using the Gell and Coombs classification.
• Evaluate strategies to manage hypersensitivity reactions during biologic therapies.
• Analyze the pharmacological differences between biologics and small-molecule drugs, including their therapeutic implications.
• Identify the systemic syndromes associated with biologic therapies and their underlying mechanisms.

Who Should Do This Course

This course is specifically designed for Registered Nurses (RNs) and Nurse Practitioners involved in administering, monitoring, or educating patients on biologic therapies. It is ideal for professionals working in:

• Oncology
• Rheumatology
• Dermatology
• Gastroenterology
• Infectious Disease
• Allergy and Immunology
• Pediatric Nursing
• Critical Care
• Transplant Units

It is also recommended for nurses seeking to expand their pharmacological knowledge and clinical competency related to high-risk, immunologically active therapies.

Did You Know?

• Biologics represent over 40% of the total pharmaceutical spending in the U.S., despite being prescribed to less than 2% of patients. (IQVIA, 2022)
• Monoclonal antibodies have revolutionized cancer treatment and are used in more than 20 different types of cancers. (National Cancer Institute, 2021)
• Hypersensitivity reactions to biologics can occur in up to 10% of patients and are more common during the first infusion. (JACI In Practice, 2020)
• Biosimilars can reduce treatment costs by up to 30%, improving access to biologic therapies. (FDA, 2021)
• The Biologics Control Act of 1902 was the first U.S. law to ensure the safety of biologic products.